TransMedics Group (NASDAQ:TMDX – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from $174.00 to $142.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 49.58% from the company’s current price.
A number of other equities research analysts have also recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of TransMedics Group in a research note on Monday, March 16th. JPMorgan Chase & Co. upped their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Piper Sandler upped their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $148.78.
View Our Latest Analysis on TransMedics Group
TransMedics Group Trading Down 2.2%
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 31.43% and a return on equity of 30.17%. The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.48 million. During the same quarter in the previous year, the firm posted $0.70 EPS. The company’s revenue was up 21.2% on a year-over-year basis. As a group, analysts anticipate that TransMedics Group will post 2.48 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the sale, the director owned 2,866 shares in the company, valued at approximately $428,810.92. This represents a 29.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the sale, the chief financial officer owned 14,689 shares in the company, valued at approximately $2,162,367.69. This trade represents a 33.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 16,205 shares of company stock worth $2,353,002 in the last quarter. Company insiders own 6.90% of the company’s stock.
Institutional Investors Weigh In On TransMedics Group
Large investors have recently added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. raised its stake in TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after acquiring an additional 206 shares during the period. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group during the 3rd quarter worth $29,000. Allworth Financial LP increased its position in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Optiver Holding B.V. increased its position in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the period. Finally, Parallel Advisors LLC increased its position in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. Institutional investors own 99.67% of the company’s stock.
TransMedics Group Company Profile
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Read More
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
